nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolasetron—CYP2C9—Sorafenib—liver cancer	0.14	0.294	CbGbCtD
Dolasetron—CYP2D6—Sorafenib—liver cancer	0.128	0.269	CbGbCtD
Dolasetron—CYP3A4—Sorafenib—liver cancer	0.0813	0.171	CbGbCtD
Dolasetron—CYP2D6—Doxorubicin—liver cancer	0.0776	0.163	CbGbCtD
Dolasetron—CYP3A4—Doxorubicin—liver cancer	0.0493	0.104	CbGbCtD
Dolasetron—Haematoma—Sorafenib—liver cancer	0.00994	0.024	CcSEcCtD
Dolasetron—Gravitational oedema—Epirubicin—liver cancer	0.00946	0.0228	CcSEcCtD
Dolasetron—Gravitational oedema—Doxorubicin—liver cancer	0.00875	0.0211	CcSEcCtD
Dolasetron—Myocardial ischaemia—Sorafenib—liver cancer	0.00777	0.0188	CcSEcCtD
Dolasetron—Influenza like illness—Sorafenib—liver cancer	0.00607	0.0146	CcSEcCtD
Dolasetron—Prothrombin level increased—Epirubicin—liver cancer	0.00563	0.0136	CcSEcCtD
Dolasetron—Prothrombin level increased—Doxorubicin—liver cancer	0.00521	0.0126	CcSEcCtD
Dolasetron—Hepatic function abnormal—Sorafenib—liver cancer	0.00519	0.0125	CcSEcCtD
Dolasetron—Renal failure acute—Sorafenib—liver cancer	0.00491	0.0119	CcSEcCtD
Dolasetron—Bundle branch block—Epirubicin—liver cancer	0.00458	0.011	CcSEcCtD
Dolasetron—Bundle branch block—Doxorubicin—liver cancer	0.00423	0.0102	CcSEcCtD
Dolasetron—Dehydration—Sorafenib—liver cancer	0.00422	0.0102	CcSEcCtD
Dolasetron—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00408	0.00985	CcSEcCtD
Dolasetron—Alanine aminotransferase increased—Sorafenib—liver cancer	0.004	0.00965	CcSEcCtD
Dolasetron—Pancreatitis—Sorafenib—liver cancer	0.00384	0.00927	CcSEcCtD
Dolasetron—Transaminases increased—Epirubicin—liver cancer	0.0038	0.00916	CcSEcCtD
Dolasetron—Pneumonia—Sorafenib—liver cancer	0.00352	0.00848	CcSEcCtD
Dolasetron—Transaminases increased—Doxorubicin—liver cancer	0.00351	0.00847	CcSEcCtD
Dolasetron—Acute coronary syndrome—Sorafenib—liver cancer	0.00345	0.00831	CcSEcCtD
Dolasetron—Myocardial infarction—Sorafenib—liver cancer	0.00343	0.00827	CcSEcCtD
Dolasetron—Jaundice—Sorafenib—liver cancer	0.00341	0.00822	CcSEcCtD
Dolasetron—Stomatitis—Sorafenib—liver cancer	0.00341	0.00822	CcSEcCtD
Dolasetron—Epistaxis—Sorafenib—liver cancer	0.0033	0.00795	CcSEcCtD
Dolasetron—Ventricular arrhythmia—Epirubicin—liver cancer	0.00312	0.00753	CcSEcCtD
Dolasetron—Tinnitus—Sorafenib—liver cancer	0.00293	0.00706	CcSEcCtD
Dolasetron—Flushing—Sorafenib—liver cancer	0.00291	0.00703	CcSEcCtD
Dolasetron—Ventricular arrhythmia—Doxorubicin—liver cancer	0.00289	0.00696	CcSEcCtD
Dolasetron—Injection site pain—Epirubicin—liver cancer	0.00283	0.00682	CcSEcCtD
Dolasetron—Arrhythmia—Sorafenib—liver cancer	0.0028	0.00676	CcSEcCtD
Dolasetron—Dysgeusia—Sorafenib—liver cancer	0.00267	0.00645	CcSEcCtD
Dolasetron—Injection site pain—Doxorubicin—liver cancer	0.00262	0.00631	CcSEcCtD
Dolasetron—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00254	0.00613	CcSEcCtD
Dolasetron—Anaemia—Sorafenib—liver cancer	0.00252	0.00609	CcSEcCtD
Dolasetron—Oliguria—Epirubicin—liver cancer	0.00251	0.00605	CcSEcCtD
Dolasetron—Angioedema—Sorafenib—liver cancer	0.0025	0.00602	CcSEcCtD
Dolasetron—Syncope—Sorafenib—liver cancer	0.00245	0.00591	CcSEcCtD
Dolasetron—Loss of consciousness—Sorafenib—liver cancer	0.0024	0.00579	CcSEcCtD
Dolasetron—Cough—Sorafenib—liver cancer	0.00238	0.00575	CcSEcCtD
Dolasetron—Atrioventricular block—Epirubicin—liver cancer	0.00238	0.00574	CcSEcCtD
Dolasetron—Hypertension—Sorafenib—liver cancer	0.00236	0.00569	CcSEcCtD
Dolasetron—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.00235	0.00567	CcSEcCtD
Dolasetron—Arthralgia—Sorafenib—liver cancer	0.00233	0.00561	CcSEcCtD
Dolasetron—Myalgia—Sorafenib—liver cancer	0.00233	0.00561	CcSEcCtD
Dolasetron—Oliguria—Doxorubicin—liver cancer	0.00232	0.00559	CcSEcCtD
Dolasetron—Ventricular tachycardia—Epirubicin—liver cancer	0.00231	0.00557	CcSEcCtD
Dolasetron—Phosphatase alkaline increased—Epirubicin—liver cancer	0.00231	0.00557	CcSEcCtD
Dolasetron—Hiccups—Epirubicin—liver cancer	0.00231	0.00557	CcSEcCtD
Dolasetron—Dry mouth—Sorafenib—liver cancer	0.00227	0.00549	CcSEcCtD
Dolasetron—Eructation—Epirubicin—liver cancer	0.00227	0.00547	CcSEcCtD
Dolasetron—Influenza like illness—Epirubicin—liver cancer	0.00224	0.00541	CcSEcCtD
Dolasetron—Anaphylactic shock—Sorafenib—liver cancer	0.00223	0.00538	CcSEcCtD
Dolasetron—Atrioventricular block—Doxorubicin—liver cancer	0.0022	0.00531	CcSEcCtD
Dolasetron—Shock—Sorafenib—liver cancer	0.00219	0.00529	CcSEcCtD
Dolasetron—Thrombocytopenia—Sorafenib—liver cancer	0.00218	0.00527	CcSEcCtD
Dolasetron—Aplastic anaemia—Epirubicin—liver cancer	0.00217	0.00523	CcSEcCtD
Dolasetron—Ventricular tachycardia—Doxorubicin—liver cancer	0.00214	0.00516	CcSEcCtD
Dolasetron—Hiccups—Doxorubicin—liver cancer	0.00214	0.00516	CcSEcCtD
Dolasetron—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.00214	0.00516	CcSEcCtD
Dolasetron—Anorexia—Sorafenib—liver cancer	0.00212	0.00513	CcSEcCtD
Dolasetron—Eructation—Doxorubicin—liver cancer	0.0021	0.00506	CcSEcCtD
Dolasetron—Influenza like illness—Doxorubicin—liver cancer	0.00207	0.00501	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00203	0.0049	CcSEcCtD
Dolasetron—Abnormal vision—Epirubicin—liver cancer	0.00201	0.00486	CcSEcCtD
Dolasetron—Aplastic anaemia—Doxorubicin—liver cancer	0.00201	0.00484	CcSEcCtD
Dolasetron—Sepsis—Epirubicin—liver cancer	0.002	0.00483	CcSEcCtD
Dolasetron—Dyspnoea—Sorafenib—liver cancer	0.00199	0.00479	CcSEcCtD
Dolasetron—Dyspepsia—Sorafenib—liver cancer	0.00196	0.00473	CcSEcCtD
Dolasetron—Phlebitis—Epirubicin—liver cancer	0.00195	0.00469	CcSEcCtD
Dolasetron—Decreased appetite—Sorafenib—liver cancer	0.00194	0.00468	CcSEcCtD
Dolasetron—Thrombophlebitis—Epirubicin—liver cancer	0.00194	0.00467	CcSEcCtD
Dolasetron—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00193	0.00465	CcSEcCtD
Dolasetron—Fatigue—Sorafenib—liver cancer	0.00192	0.00464	CcSEcCtD
Dolasetron—Hepatic function abnormal—Epirubicin—liver cancer	0.00192	0.00463	CcSEcCtD
Dolasetron—Pain—Sorafenib—liver cancer	0.00191	0.0046	CcSEcCtD
Dolasetron—Constipation—Sorafenib—liver cancer	0.00191	0.0046	CcSEcCtD
Dolasetron—Vascular purpura—Epirubicin—liver cancer	0.00187	0.00452	CcSEcCtD
Dolasetron—Abnormal vision—Doxorubicin—liver cancer	0.00186	0.0045	CcSEcCtD
Dolasetron—Sepsis—Doxorubicin—liver cancer	0.00185	0.00447	CcSEcCtD
Dolasetron—Gastrointestinal pain—Sorafenib—liver cancer	0.00182	0.0044	CcSEcCtD
Dolasetron—Renal failure acute—Epirubicin—liver cancer	0.00182	0.00438	CcSEcCtD
Dolasetron—Phlebitis—Doxorubicin—liver cancer	0.0018	0.00434	CcSEcCtD
Dolasetron—Thrombophlebitis—Doxorubicin—liver cancer	0.00179	0.00432	CcSEcCtD
Dolasetron—Increased appetite—Epirubicin—liver cancer	0.00178	0.0043	CcSEcCtD
Dolasetron—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00178	0.0043	CcSEcCtD
Dolasetron—Hepatic function abnormal—Doxorubicin—liver cancer	0.00177	0.00428	CcSEcCtD
Dolasetron—Urticaria—Sorafenib—liver cancer	0.00177	0.00427	CcSEcCtD
Dolasetron—Abdominal pain—Sorafenib—liver cancer	0.00176	0.00425	CcSEcCtD
Dolasetron—Body temperature increased—Sorafenib—liver cancer	0.00176	0.00425	CcSEcCtD
Dolasetron—Purpura—Epirubicin—liver cancer	0.00174	0.0042	CcSEcCtD
Dolasetron—Vascular purpura—Doxorubicin—liver cancer	0.00173	0.00418	CcSEcCtD
Dolasetron—Anaphylactoid reaction—Epirubicin—liver cancer	0.00173	0.00418	CcSEcCtD
Dolasetron—Renal failure acute—Doxorubicin—liver cancer	0.00168	0.00405	CcSEcCtD
Dolasetron—Increased appetite—Doxorubicin—liver cancer	0.00165	0.00398	CcSEcCtD
Dolasetron—Hypersensitivity—Sorafenib—liver cancer	0.00164	0.00396	CcSEcCtD
Dolasetron—Face oedema—Epirubicin—liver cancer	0.00162	0.0039	CcSEcCtD
Dolasetron—Purpura—Doxorubicin—liver cancer	0.00161	0.00388	CcSEcCtD
Dolasetron—Anaphylactoid reaction—Doxorubicin—liver cancer	0.0016	0.00387	CcSEcCtD
Dolasetron—Asthenia—Sorafenib—liver cancer	0.0016	0.00386	CcSEcCtD
Dolasetron—Cardiac arrest—Epirubicin—liver cancer	0.00159	0.00385	CcSEcCtD
Dolasetron—Pruritus—Sorafenib—liver cancer	0.00158	0.00381	CcSEcCtD
Dolasetron—Ataxia—Epirubicin—liver cancer	0.00158	0.0038	CcSEcCtD
Dolasetron—Dehydration—Epirubicin—liver cancer	0.00156	0.00376	CcSEcCtD
Dolasetron—Orthostatic hypotension—Epirubicin—liver cancer	0.00153	0.00369	CcSEcCtD
Dolasetron—Diarrhoea—Sorafenib—liver cancer	0.00153	0.00368	CcSEcCtD
Dolasetron—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00151	0.00364	CcSEcCtD
Dolasetron—Face oedema—Doxorubicin—liver cancer	0.0015	0.00361	CcSEcCtD
Dolasetron—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00148	0.00357	CcSEcCtD
Dolasetron—Cardiac arrest—Doxorubicin—liver cancer	0.00147	0.00356	CcSEcCtD
Dolasetron—Dizziness—Sorafenib—liver cancer	0.00147	0.00356	CcSEcCtD
Dolasetron—Abdominal distension—Epirubicin—liver cancer	0.00146	0.00352	CcSEcCtD
Dolasetron—Ataxia—Doxorubicin—liver cancer	0.00146	0.00352	CcSEcCtD
Dolasetron—Dehydration—Doxorubicin—liver cancer	0.00144	0.00348	CcSEcCtD
Dolasetron—Pancreatitis—Epirubicin—liver cancer	0.00142	0.00343	CcSEcCtD
Dolasetron—Orthostatic hypotension—Doxorubicin—liver cancer	0.00142	0.00342	CcSEcCtD
Dolasetron—Rash—Sorafenib—liver cancer	0.00141	0.00339	CcSEcCtD
Dolasetron—Dermatitis—Sorafenib—liver cancer	0.0014	0.00339	CcSEcCtD
Dolasetron—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.0014	0.00337	CcSEcCtD
Dolasetron—Headache—Sorafenib—liver cancer	0.0014	0.00337	CcSEcCtD
Dolasetron—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00137	0.0033	CcSEcCtD
Dolasetron—Dysuria—Epirubicin—liver cancer	0.00135	0.00327	CcSEcCtD
Dolasetron—Abdominal distension—Doxorubicin—liver cancer	0.00135	0.00326	CcSEcCtD
Dolasetron—Pancreatitis—Doxorubicin—liver cancer	0.00131	0.00317	CcSEcCtD
Dolasetron—Pneumonia—Epirubicin—liver cancer	0.0013	0.00313	CcSEcCtD
Dolasetron—Drowsiness—Epirubicin—liver cancer	0.00129	0.00312	CcSEcCtD
Dolasetron—Jaundice—Epirubicin—liver cancer	0.00126	0.00304	CcSEcCtD
Dolasetron—Stomatitis—Epirubicin—liver cancer	0.00126	0.00304	CcSEcCtD
Dolasetron—Dysuria—Doxorubicin—liver cancer	0.00125	0.00302	CcSEcCtD
Dolasetron—Haematuria—Epirubicin—liver cancer	0.00123	0.00297	CcSEcCtD
Dolasetron—Epistaxis—Epirubicin—liver cancer	0.00122	0.00294	CcSEcCtD
Dolasetron—Pneumonia—Doxorubicin—liver cancer	0.0012	0.0029	CcSEcCtD
Dolasetron—Drowsiness—Doxorubicin—liver cancer	0.0012	0.00288	CcSEcCtD
Dolasetron—Bradycardia—Epirubicin—liver cancer	0.00118	0.00285	CcSEcCtD
Dolasetron—Stomatitis—Doxorubicin—liver cancer	0.00116	0.00281	CcSEcCtD
Dolasetron—Jaundice—Doxorubicin—liver cancer	0.00116	0.00281	CcSEcCtD
Dolasetron—Oedema peripheral—Epirubicin—liver cancer	0.00114	0.00276	CcSEcCtD
Dolasetron—Haematuria—Doxorubicin—liver cancer	0.00114	0.00275	CcSEcCtD
Dolasetron—Epistaxis—Doxorubicin—liver cancer	0.00113	0.00272	CcSEcCtD
Dolasetron—Visual impairment—Epirubicin—liver cancer	0.00112	0.0027	CcSEcCtD
Dolasetron—Bradycardia—Doxorubicin—liver cancer	0.00109	0.00264	CcSEcCtD
Dolasetron—Tinnitus—Epirubicin—liver cancer	0.00108	0.00261	CcSEcCtD
Dolasetron—Flushing—Epirubicin—liver cancer	0.00108	0.0026	CcSEcCtD
Dolasetron—Oedema peripheral—Doxorubicin—liver cancer	0.00106	0.00255	CcSEcCtD
Dolasetron—Chills—Epirubicin—liver cancer	0.00104	0.00251	CcSEcCtD
Dolasetron—Arrhythmia—Epirubicin—liver cancer	0.00104	0.0025	CcSEcCtD
Dolasetron—Visual impairment—Doxorubicin—liver cancer	0.00103	0.00249	CcSEcCtD
Dolasetron—Tinnitus—Doxorubicin—liver cancer	0.001	0.00241	CcSEcCtD
Dolasetron—CYP3A4—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.000999	0.00912	CbGpPWpGaD
Dolasetron—Flushing—Doxorubicin—liver cancer	0.000996	0.0024	CcSEcCtD
Dolasetron—Flatulence—Epirubicin—liver cancer	0.000995	0.0024	CcSEcCtD
Dolasetron—Dysgeusia—Epirubicin—liver cancer	0.000988	0.00238	CcSEcCtD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.000968	0.00884	CbGpPWpGaD
Dolasetron—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.000964	0.0088	CbGpPWpGaD
Dolasetron—Chills—Doxorubicin—liver cancer	0.000963	0.00232	CcSEcCtD
Dolasetron—Arrhythmia—Doxorubicin—liver cancer	0.000958	0.00231	CcSEcCtD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.000951	0.00869	CbGpPWpGaD
Dolasetron—CYP2D6—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00094	0.00858	CbGpPWpGaD
Dolasetron—Ill-defined disorder—Epirubicin—liver cancer	0.000936	0.00226	CcSEcCtD
Dolasetron—Anaemia—Epirubicin—liver cancer	0.000933	0.00225	CcSEcCtD
Dolasetron—CYP2C9—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000932	0.00851	CbGpPWpGaD
Dolasetron—Agitation—Epirubicin—liver cancer	0.000928	0.00224	CcSEcCtD
Dolasetron—Flatulence—Doxorubicin—liver cancer	0.00092	0.00222	CcSEcCtD
Dolasetron—Dysgeusia—Doxorubicin—liver cancer	0.000915	0.00221	CcSEcCtD
Dolasetron—Malaise—Epirubicin—liver cancer	0.00091	0.0022	CcSEcCtD
Dolasetron—Vertigo—Epirubicin—liver cancer	0.000907	0.00219	CcSEcCtD
Dolasetron—Syncope—Epirubicin—liver cancer	0.000905	0.00218	CcSEcCtD
Dolasetron—Palpitations—Epirubicin—liver cancer	0.000892	0.00215	CcSEcCtD
Dolasetron—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00089	0.00813	CbGpPWpGaD
Dolasetron—Loss of consciousness—Epirubicin—liver cancer	0.000887	0.00214	CcSEcCtD
Dolasetron—CYP2D6—Xenobiotics—CYP1A1—liver cancer	0.000886	0.00809	CbGpPWpGaD
Dolasetron—Cough—Epirubicin—liver cancer	0.000881	0.00213	CcSEcCtD
Dolasetron—CYP2C9—Xenobiotics—CYP1A1—liver cancer	0.000878	0.00802	CbGpPWpGaD
Dolasetron—Convulsion—Epirubicin—liver cancer	0.000875	0.00211	CcSEcCtD
Dolasetron—Hypertension—Epirubicin—liver cancer	0.000871	0.0021	CcSEcCtD
Dolasetron—Ill-defined disorder—Doxorubicin—liver cancer	0.000867	0.00209	CcSEcCtD
Dolasetron—Anaemia—Doxorubicin—liver cancer	0.000863	0.00208	CcSEcCtD
Dolasetron—Arthralgia—Epirubicin—liver cancer	0.000859	0.00207	CcSEcCtD
Dolasetron—Myalgia—Epirubicin—liver cancer	0.000859	0.00207	CcSEcCtD
Dolasetron—Chest pain—Epirubicin—liver cancer	0.000859	0.00207	CcSEcCtD
Dolasetron—Agitation—Doxorubicin—liver cancer	0.000858	0.00207	CcSEcCtD
Dolasetron—Anxiety—Epirubicin—liver cancer	0.000856	0.00207	CcSEcCtD
Dolasetron—CYP2D6—Tamoxifen metabolism—CYP1A1—liver cancer	0.000852	0.00778	CbGpPWpGaD
Dolasetron—Discomfort—Epirubicin—liver cancer	0.000849	0.00205	CcSEcCtD
Dolasetron—CYP2C9—Tamoxifen metabolism—CYP1A1—liver cancer	0.000844	0.00771	CbGpPWpGaD
Dolasetron—Malaise—Doxorubicin—liver cancer	0.000842	0.00203	CcSEcCtD
Dolasetron—Dry mouth—Epirubicin—liver cancer	0.00084	0.00203	CcSEcCtD
Dolasetron—Vertigo—Doxorubicin—liver cancer	0.000839	0.00202	CcSEcCtD
Dolasetron—Syncope—Doxorubicin—liver cancer	0.000838	0.00202	CcSEcCtD
Dolasetron—Confusional state—Epirubicin—liver cancer	0.000831	0.002	CcSEcCtD
Dolasetron—Palpitations—Doxorubicin—liver cancer	0.000825	0.00199	CcSEcCtD
Dolasetron—Oedema—Epirubicin—liver cancer	0.000824	0.00199	CcSEcCtD
Dolasetron—Anaphylactic shock—Epirubicin—liver cancer	0.000824	0.00199	CcSEcCtD
Dolasetron—Loss of consciousness—Doxorubicin—liver cancer	0.000821	0.00198	CcSEcCtD
Dolasetron—Cough—Doxorubicin—liver cancer	0.000815	0.00197	CcSEcCtD
Dolasetron—Shock—Epirubicin—liver cancer	0.00081	0.00196	CcSEcCtD
Dolasetron—Convulsion—Doxorubicin—liver cancer	0.000809	0.00195	CcSEcCtD
Dolasetron—Thrombocytopenia—Epirubicin—liver cancer	0.000807	0.00195	CcSEcCtD
Dolasetron—Hypertension—Doxorubicin—liver cancer	0.000806	0.00195	CcSEcCtD
Dolasetron—CYP3A4—Xenobiotics—CYP2E1—liver cancer	0.000806	0.00736	CbGpPWpGaD
Dolasetron—Tachycardia—Epirubicin—liver cancer	0.000804	0.00194	CcSEcCtD
Dolasetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000799	0.0073	CbGpPWpGaD
Dolasetron—Hyperhidrosis—Epirubicin—liver cancer	0.000796	0.00192	CcSEcCtD
Dolasetron—Chest pain—Doxorubicin—liver cancer	0.000795	0.00192	CcSEcCtD
Dolasetron—Arthralgia—Doxorubicin—liver cancer	0.000795	0.00192	CcSEcCtD
Dolasetron—Myalgia—Doxorubicin—liver cancer	0.000795	0.00192	CcSEcCtD
Dolasetron—Anxiety—Doxorubicin—liver cancer	0.000792	0.00191	CcSEcCtD
Dolasetron—Discomfort—Doxorubicin—liver cancer	0.000786	0.0019	CcSEcCtD
Dolasetron—Anorexia—Epirubicin—liver cancer	0.000785	0.00189	CcSEcCtD
Dolasetron—Dry mouth—Doxorubicin—liver cancer	0.000778	0.00188	CcSEcCtD
Dolasetron—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	0.000775	0.00708	CbGpPWpGaD
Dolasetron—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	0.000771	0.00704	CbGpPWpGaD
Dolasetron—Hypotension—Epirubicin—liver cancer	0.00077	0.00186	CcSEcCtD
Dolasetron—Confusional state—Doxorubicin—liver cancer	0.000769	0.00185	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000767	0.00701	CbGpPWpGaD
Dolasetron—Anaphylactic shock—Doxorubicin—liver cancer	0.000762	0.00184	CcSEcCtD
Dolasetron—Oedema—Doxorubicin—liver cancer	0.000762	0.00184	CcSEcCtD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000762	0.00696	CbGpPWpGaD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000755	0.0069	CbGpPWpGaD
Dolasetron—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000751	0.00181	CcSEcCtD
Dolasetron—Shock—Doxorubicin—liver cancer	0.00075	0.00181	CcSEcCtD
Dolasetron—Thrombocytopenia—Doxorubicin—liver cancer	0.000746	0.0018	CcSEcCtD
Dolasetron—Tachycardia—Doxorubicin—liver cancer	0.000744	0.00179	CcSEcCtD
Dolasetron—Paraesthesia—Epirubicin—liver cancer	0.00074	0.00178	CcSEcCtD
Dolasetron—Hyperhidrosis—Doxorubicin—liver cancer	0.000737	0.00178	CcSEcCtD
Dolasetron—Dyspnoea—Epirubicin—liver cancer	0.000734	0.00177	CcSEcCtD
Dolasetron—Somnolence—Epirubicin—liver cancer	0.000732	0.00177	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000732	0.00668	CbGpPWpGaD
Dolasetron—Anorexia—Doxorubicin—liver cancer	0.000727	0.00175	CcSEcCtD
Dolasetron—Dyspepsia—Epirubicin—liver cancer	0.000725	0.00175	CcSEcCtD
Dolasetron—CYP2C9—Arachidonic acid metabolism—HPGDS—liver cancer	0.00072	0.00658	CbGpPWpGaD
Dolasetron—Decreased appetite—Epirubicin—liver cancer	0.000716	0.00173	CcSEcCtD
Dolasetron—Hypotension—Doxorubicin—liver cancer	0.000712	0.00172	CcSEcCtD
Dolasetron—Fatigue—Epirubicin—liver cancer	0.00071	0.00171	CcSEcCtD
Dolasetron—Constipation—Epirubicin—liver cancer	0.000704	0.0017	CcSEcCtD
Dolasetron—Pain—Epirubicin—liver cancer	0.000704	0.0017	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000702	0.00641	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000702	0.00641	CbGpPWpGaD
Dolasetron—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000694	0.00168	CcSEcCtD
Dolasetron—CYP2D6—Biological oxidations—UGDH—liver cancer	0.000693	0.00633	CbGpPWpGaD
Dolasetron—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.000692	0.00632	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—UGDH—liver cancer	0.000687	0.00627	CbGpPWpGaD
Dolasetron—Paraesthesia—Doxorubicin—liver cancer	0.000684	0.00165	CcSEcCtD
Dolasetron—Dyspnoea—Doxorubicin—liver cancer	0.00068	0.00164	CcSEcCtD
Dolasetron—Feeling abnormal—Epirubicin—liver cancer	0.000679	0.00164	CcSEcCtD
Dolasetron—Somnolence—Doxorubicin—liver cancer	0.000678	0.00163	CcSEcCtD
Dolasetron—Gastrointestinal pain—Epirubicin—liver cancer	0.000674	0.00163	CcSEcCtD
Dolasetron—Dyspepsia—Doxorubicin—liver cancer	0.000671	0.00162	CcSEcCtD
Dolasetron—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	0.000665	0.00607	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000664	0.00606	CbGpPWpGaD
Dolasetron—Decreased appetite—Doxorubicin—liver cancer	0.000663	0.0016	CcSEcCtD
Dolasetron—CYP2D6—Melatonin metabolism and effects—CYP1A1—liver cancer	0.000658	0.00601	CbGpPWpGaD
Dolasetron—Fatigue—Doxorubicin—liver cancer	0.000657	0.00159	CcSEcCtD
Dolasetron—Urticaria—Epirubicin—liver cancer	0.000654	0.00158	CcSEcCtD
Dolasetron—Constipation—Doxorubicin—liver cancer	0.000652	0.00157	CcSEcCtD
Dolasetron—Pain—Doxorubicin—liver cancer	0.000652	0.00157	CcSEcCtD
Dolasetron—Abdominal pain—Epirubicin—liver cancer	0.000651	0.00157	CcSEcCtD
Dolasetron—Body temperature increased—Epirubicin—liver cancer	0.000651	0.00157	CcSEcCtD
Dolasetron—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	0.00063	0.00575	CbGpPWpGaD
Dolasetron—Feeling abnormal—Doxorubicin—liver cancer	0.000628	0.00152	CcSEcCtD
Dolasetron—Gastrointestinal pain—Doxorubicin—liver cancer	0.000623	0.0015	CcSEcCtD
Dolasetron—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000614	0.00561	CbGpPWpGaD
Dolasetron—Hypersensitivity—Epirubicin—liver cancer	0.000607	0.00146	CcSEcCtD
Dolasetron—Urticaria—Doxorubicin—liver cancer	0.000606	0.00146	CcSEcCtD
Dolasetron—CYP3A4—Irinotecan Pathway—APC—liver cancer	0.000603	0.00551	CbGpPWpGaD
Dolasetron—Abdominal pain—Doxorubicin—liver cancer	0.000603	0.00145	CcSEcCtD
Dolasetron—Body temperature increased—Doxorubicin—liver cancer	0.000603	0.00145	CcSEcCtD
Dolasetron—Asthenia—Epirubicin—liver cancer	0.000591	0.00143	CcSEcCtD
Dolasetron—Pruritus—Epirubicin—liver cancer	0.000583	0.00141	CcSEcCtD
Dolasetron—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.000579	0.00529	CbGpPWpGaD
Dolasetron—Diarrhoea—Epirubicin—liver cancer	0.000564	0.00136	CcSEcCtD
Dolasetron—Hypersensitivity—Doxorubicin—liver cancer	0.000562	0.00135	CcSEcCtD
Dolasetron—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.000557	0.00509	CbGpPWpGaD
Dolasetron—Asthenia—Doxorubicin—liver cancer	0.000547	0.00132	CcSEcCtD
Dolasetron—Dizziness—Epirubicin—liver cancer	0.000545	0.00131	CcSEcCtD
Dolasetron—Pruritus—Doxorubicin—liver cancer	0.000539	0.0013	CcSEcCtD
Dolasetron—CYP2C9—Arachidonic acid metabolism—GGT1—liver cancer	0.000539	0.00492	CbGpPWpGaD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000527	0.00482	CbGpPWpGaD
Dolasetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000525	0.0048	CbGpPWpGaD
Dolasetron—Diarrhoea—Doxorubicin—liver cancer	0.000522	0.00126	CcSEcCtD
Dolasetron—Rash—Epirubicin—liver cancer	0.000519	0.00125	CcSEcCtD
Dolasetron—Dermatitis—Epirubicin—liver cancer	0.000519	0.00125	CcSEcCtD
Dolasetron—Headache—Epirubicin—liver cancer	0.000516	0.00125	CcSEcCtD
Dolasetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000512	0.00468	CbGpPWpGaD
Dolasetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000508	0.00464	CbGpPWpGaD
Dolasetron—CYP2D6—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000505	0.00461	CbGpPWpGaD
Dolasetron—Dizziness—Doxorubicin—liver cancer	0.000504	0.00122	CcSEcCtD
Dolasetron—CYP2C9—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000501	0.00457	CbGpPWpGaD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000498	0.00455	CbGpPWpGaD
Dolasetron—Rash—Doxorubicin—liver cancer	0.000481	0.00116	CcSEcCtD
Dolasetron—Dermatitis—Doxorubicin—liver cancer	0.00048	0.00116	CcSEcCtD
Dolasetron—Headache—Doxorubicin—liver cancer	0.000477	0.00115	CcSEcCtD
Dolasetron—HTR3A—Ion channel transport—RAF1—liver cancer	0.000459	0.00419	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—UGDH—liver cancer	0.000453	0.00414	CbGpPWpGaD
Dolasetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000434	0.00397	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—CASP3—liver cancer	0.000425	0.00388	CbGpPWpGaD
Dolasetron—CYP2C9—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000422	0.00385	CbGpPWpGaD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000415	0.00379	CbGpPWpGaD
Dolasetron—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.000414	0.00378	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—JUN—liver cancer	0.000412	0.00377	CbGpPWpGaD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000411	0.00376	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—CTNNB1—liver cancer	0.000409	0.00374	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—NR1H4—liver cancer	0.000405	0.0037	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—NR1H4—liver cancer	0.000401	0.00366	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTA3—liver cancer	0.000398	0.00363	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTA3—liver cancer	0.000394	0.0036	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTA3—liver cancer	0.000392	0.00358	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTA3—liver cancer	0.000389	0.00355	CbGpPWpGaD
Dolasetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000368	0.00336	CbGpPWpGaD
Dolasetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000365	0.00333	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTA4—liver cancer	0.000364	0.00332	CbGpPWpGaD
Dolasetron—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000363	0.00331	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTA4—liver cancer	0.000361	0.00329	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—VEGFA—liver cancer	0.00036	0.00329	CbGpPWpGaD
Dolasetron—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.00036	0.00329	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTA4—liver cancer	0.000359	0.00328	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTA4—liver cancer	0.000356	0.00325	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTA2—liver cancer	0.000355	0.00324	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTA2—liver cancer	0.000352	0.00321	CbGpPWpGaD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000346	0.00316	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTA1—liver cancer	0.000342	0.00312	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTA1—liver cancer	0.000339	0.0031	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—NAT2—liver cancer	0.000338	0.00309	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—CYCS—liver cancer	0.000338	0.00309	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—NAT2—liver cancer	0.000335	0.00306	CbGpPWpGaD
Dolasetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000335	0.00306	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—NAT2—liver cancer	0.000334	0.00305	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—NAT2—liver cancer	0.000331	0.00302	CbGpPWpGaD
Dolasetron—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.00033	0.00302	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—TNF—liver cancer	0.000309	0.00282	CbGpPWpGaD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000298	0.00272	CbGpPWpGaD
Dolasetron—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000297	0.00272	CbGpPWpGaD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000296	0.0027	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000294	0.00268	CbGpPWpGaD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000286	0.00262	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GPX3—liver cancer	0.000284	0.00259	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GPX3—liver cancer	0.000281	0.00257	CbGpPWpGaD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000271	0.00248	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—HPGDS—liver cancer	0.00027	0.00247	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—HPGDS—liver cancer	0.000268	0.00245	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.000265	0.00242	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.00026	0.00238	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.000257	0.00234	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—IL6—liver cancer	0.000249	0.00228	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000248	0.00226	CbGpPWpGaD
Dolasetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.00024	0.0022	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000238	0.00217	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—PPARA—liver cancer	0.000238	0.00217	CbGpPWpGaD
Dolasetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000237	0.00217	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000235	0.00214	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.000232	0.00212	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000224	0.00204	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000221	0.00202	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—CYP2E1—liver cancer	0.00022	0.00201	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—CYP2E1—liver cancer	0.000219	0.002	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000218	0.00199	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—CYP2E1—liver cancer	0.000217	0.00199	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—CYP2E1—liver cancer	0.000216	0.00197	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GGT1—liver cancer	0.000202	0.00185	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GGT1—liver cancer	0.000201	0.00183	CbGpPWpGaD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000195	0.00178	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000185	0.00169	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTP1—liver cancer	0.000182	0.00166	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTP1—liver cancer	0.00018	0.00165	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTP1—liver cancer	0.000179	0.00164	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTP1—liver cancer	0.000178	0.00162	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000177	0.00161	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ALB—liver cancer	0.000177	0.00161	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTM1—liver cancer	0.000167	0.00153	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTM1—liver cancer	0.000166	0.00151	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTM1—liver cancer	0.000165	0.0015	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTM1—liver cancer	0.000163	0.00149	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.00016	0.00146	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—RAF1—liver cancer	0.00016	0.00146	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—CYP1A1—liver cancer	0.000158	0.00145	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—CYP1A1—liver cancer	0.000157	0.00143	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—CYP1A1—liver cancer	0.000156	0.00143	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—CYP1A1—liver cancer	0.000155	0.00141	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000154	0.00141	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000144	0.00132	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000142	0.0013	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000132	0.00121	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000119	0.00109	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—UGDH—liver cancer	0.000118	0.00108	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000118	0.00108	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—UGDH—liver cancer	0.000117	0.00107	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000117	0.00107	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—EPT1—liver cancer	0.000111	0.00102	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—EPT1—liver cancer	0.00011	0.00101	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000109	0.000998	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000108	0.000984	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—TAT—liver cancer	0.000106	0.000964	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—TAT—liver cancer	0.000105	0.000956	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000104	0.000946	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000103	0.00094	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000102	0.000933	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—UGDH—liver cancer	7.75e-05	0.000707	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	7.71e-05	0.000704	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—EPT1—liver cancer	7.28e-05	0.000665	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CPT1B—liver cancer	7.18e-05	0.000655	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GLUL—liver cancer	7.18e-05	0.000655	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CPT1B—liver cancer	7.12e-05	0.00065	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GLUL—liver cancer	7.12e-05	0.00065	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NR1H4—liver cancer	6.92e-05	0.000632	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—TAT—liver cancer	6.9e-05	0.00063	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NR1H4—liver cancer	6.86e-05	0.000627	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTA3—liver cancer	6.8e-05	0.000621	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTA3—liver cancer	6.74e-05	0.000616	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTA4—liver cancer	6.22e-05	0.000568	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTA4—liver cancer	6.17e-05	0.000563	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTA2—liver cancer	6.06e-05	0.000554	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	6.03e-05	0.000551	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTA2—liver cancer	6.01e-05	0.000549	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTA1—liver cancer	5.85e-05	0.000534	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTA1—liver cancer	5.8e-05	0.00053	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NAT2—liver cancer	5.79e-05	0.000528	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NAT2—liver cancer	5.74e-05	0.000524	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ALDOB—liver cancer	5.55e-05	0.000507	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	5.51e-05	0.000504	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ALDOB—liver cancer	5.5e-05	0.000502	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CRABP1—liver cancer	5.29e-05	0.000483	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CRABP1—liver cancer	5.25e-05	0.000479	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.72e-05	0.000431	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CPT1B—liver cancer	4.69e-05	0.000429	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GLUL—liver cancer	4.69e-05	0.000429	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HPGDS—liver cancer	4.62e-05	0.000422	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HPGDS—liver cancer	4.58e-05	0.000419	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.56e-05	0.000416	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NR1H4—liver cancer	4.52e-05	0.000413	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTA3—liver cancer	4.45e-05	0.000406	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.15e-05	0.000379	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PSMD10—liver cancer	4.12e-05	0.000376	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PSMA4—liver cancer	4.12e-05	0.000376	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.1e-05	0.000374	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PSMA4—liver cancer	4.09e-05	0.000373	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PSMD10—liver cancer	4.09e-05	0.000373	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTA4—liver cancer	4.07e-05	0.000372	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GOT2—liver cancer	4.01e-05	0.000366	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GOT2—liver cancer	3.98e-05	0.000363	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTA2—liver cancer	3.96e-05	0.000362	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTA1—liver cancer	3.83e-05	0.000349	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NAT2—liver cancer	3.78e-05	0.000345	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP2E1—liver cancer	3.77e-05	0.000344	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP2E1—liver cancer	3.74e-05	0.000341	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ALDOB—liver cancer	3.63e-05	0.000331	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.62e-05	0.00033	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYCS—liver cancer	3.53e-05	0.000322	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYCS—liver cancer	3.5e-05	0.000319	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GOT1—liver cancer	3.46e-05	0.000316	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GGT1—liver cancer	3.46e-05	0.000316	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CRABP1—liver cancer	3.46e-05	0.000316	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GGT1—liver cancer	3.43e-05	0.000313	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GOT1—liver cancer	3.43e-05	0.000313	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTP1—liver cancer	3.11e-05	0.000284	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTP1—liver cancer	3.08e-05	0.000282	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HMOX1—liver cancer	3.07e-05	0.00028	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HMOX1—liver cancer	3.04e-05	0.000278	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HPGDS—liver cancer	3.02e-05	0.000276	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTM1—liver cancer	2.86e-05	0.000261	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTM1—liver cancer	2.83e-05	0.000259	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP1A1—liver cancer	2.71e-05	0.000247	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PSMA4—liver cancer	2.7e-05	0.000246	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PSMD10—liver cancer	2.7e-05	0.000246	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP1A1—liver cancer	2.69e-05	0.000245	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GOT2—liver cancer	2.62e-05	0.000239	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—MTHFR—liver cancer	2.53e-05	0.000231	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—MTHFR—liver cancer	2.5e-05	0.000229	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PPARA—liver cancer	2.48e-05	0.000226	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP2E1—liver cancer	2.46e-05	0.000225	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PPARA—liver cancer	2.46e-05	0.000224	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYCS—liver cancer	2.31e-05	0.000211	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GGT1—liver cancer	2.26e-05	0.000207	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GOT1—liver cancer	2.26e-05	0.000207	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.21e-05	0.000201	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CG—liver cancer	2.12e-05	0.000194	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CG—liver cancer	2.1e-05	0.000192	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PPARG—liver cancer	2.05e-05	0.000187	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTP1—liver cancer	2.03e-05	0.000186	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PPARG—liver cancer	2.03e-05	0.000185	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HMOX1—liver cancer	2e-05	0.000183	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTM1—liver cancer	1.87e-05	0.000171	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CD—liver cancer	1.87e-05	0.00017	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CD—liver cancer	1.85e-05	0.000169	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ALB—liver cancer	1.84e-05	0.000168	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ALB—liver cancer	1.83e-05	0.000167	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP1A1—liver cancer	1.77e-05	0.000162	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—MTHFR—liver cancer	1.65e-05	0.000151	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CB—liver cancer	1.63e-05	0.000148	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PPARA—liver cancer	1.62e-05	0.000148	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CB—liver cancer	1.61e-05	0.000147	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CG—liver cancer	1.39e-05	0.000127	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PPARG—liver cancer	1.34e-05	0.000122	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CD—liver cancer	1.22e-05	0.000111	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ALB—liver cancer	1.2e-05	0.00011	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CB—liver cancer	1.06e-05	9.71e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—PIK3CA—liver cancer	9.91e-06	9.05e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—PIK3CA—liver cancer	9.82e-06	8.97e-05	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—AKT1—liver cancer	8.1e-06	7.39e-05	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—AKT1—liver cancer	8.03e-06	7.33e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—PIK3CA—liver cancer	6.48e-06	5.92e-05	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—AKT1—liver cancer	5.29e-06	4.83e-05	CbGpPWpGaD
